Sector News

Celgene pens pact to join Bristol-Myers, Pfizer in R&D race

October 3, 2017
Life sciences

Celgene has secured an option on two preclinical assets in development at Nimbus Therapeutics. The deal gives Celgene a chance to move into the slipstreams of Bristol-Myers Squibb and Pfizer in the race to bring a TYK2 inhibitor to market.

TYK2 has attracted the interest of multiple major research groups on the strength of its role in the inflammatory response. Bristol-Myers has advanced its shot at the target, BMS-986165, into phase 2 trials in lupus and psoriasis. Pfizer is testing its TYK2-JAK1 kinase inhibitor, PF-06700841, in three phase 2 trials, which are enrolling patients with alopecia areata, ulcerative colitis and psoriasis.

Nimbus’ program has ceded a sizable head start to these drugs, but Celgene has seen enough in the preclinical data to suggest it can come from behind. That confidence is based, in part, on evidence Nimbus’ inhibitors are particularly selective for TYK2, enabling them to hit the target but not its JAK siblings.

The importance of TYK2 means there are plenty of opportunities to go around, too. A TYK2 inhibitor could treat autoimmune conditions including rheumatoid arthritis, Crohn’s disease and multiple sclerosis, as well as the indications being pursued in the clinic by Bristol-Myers and Pfizer.

“We are excited about the potential of the Nimbus immunology targets, which are based on compelling human genetic data,” Celgene R&D VP Robert Plenge, M.D., Ph.D., said in a statement. “Moreover, Nimbus’ robust in silico-based approach is very promising.”

That prompted the prolific dealmaker to put together an agreement that gives it an option to buy the program for an as-yet-undisclosed upfront payment and downstream milestones. The release of clinical trial data will trigger the buy-in decision on the TYK2 program and other assets covered by the deal. Nimbus is in charge of advancing the assets until Celgene exercises its option.

The second asset covered by the agreement is designed to block STING from activating the innate immune system in interferonopathies such as lupus. Nimbus’ agreement leaves it free to develop a small molecule agonist program with applications in immuno-oncology.

That immuno-oncology program is the only publicly disclosed part of Nimbus’ pipeline that is not yet the subject of a deal. Gilead and Genentech have already picked off other parts of the pipeline through an acquisition and licensing deal, respectively.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach